Trial Profile
A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Safinamide on Apathy in Patients With Parkinson's Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 18 Sep 2022 Results presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 15 Mar 2021 Status changed from recruiting to discontinued.
- 03 Apr 2018 New trial record